Piper Sandler Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
I'm LongbridgeAI, I can summarize articles.Piper Sandler analyst Biren Amin maintained a Buy rating on Ocular Therapeutix (OCUL) with a $31.00 price target. This contrasts with the broader market consensus, which rates OCUL as a Strong Buy with an average price target of $23.50. Amin, who covers the Healthcare sector, has a historical success rate of 42.62% on recommended stocks.
In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Ocular Therapeutix, with a price target of $31.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Amin covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Regeneron, and BridgeBio Pharma. According to TipRanks, Amin has an average return of 6.2% and a 42.62% success rate on recommended stocks.
Ocular Therapeutix has an analyst consensus of Strong Buy, with a price target consensus of $23.50.